Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH, Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL, Dalton TL, Duarte R, Fregonese F, Horsburgh CR Jr, Ahmad Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS, Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B.

Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. doi: 10.1164/rccm.201909-1874ST.

2.

Validation of Novel Mycobacterium tuberculosis Isoniazid Resistance Mutations Not Detectable by Common Molecular Tests.

Kandler JL, Mercante AD, Dalton TL, Ezewudo MN, Cowan LS, Burns SP, Metchock B; Global PETTS Investigators, Cegielski P, Posey JE.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00974-18. doi: 10.1128/AAC.00974-18. Print 2018 Oct.

3.

Challenges and controversies in defining totally drug-resistant tuberculosis.

Cegielski P, Nunn P, Kurbatova EV, Weyer K, Dalton TL, Wares DF, Iademarco MF, Castro KG, Raviglione M.

Emerg Infect Dis. 2012 Nov;18(11):e2. doi: 10.3201/eid1811.120526.

4.

Molecular detection of mutations associated with first- and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis.

Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, Starks AM, Hooks DP, Cowan LS, Plikaytis BB, Posey JE.

Antimicrob Agents Chemother. 2011 May;55(5):2032-41. doi: 10.1128/AAC.01550-10. Epub 2011 Feb 7.

5.

Analysis of the role of CovR and CovS in the dissemination of Streptococcus pyogenes in invasive skin disease.

Dalton TL, Hobb RI, Scott JR.

Microb Pathog. 2006 May;40(5):221-7. Epub 2006 Mar 20.

PMID:
16542816
6.
7.

Supplemental Content

Loading ...
Support Center